PE-22-28
Synthetic heptapeptide analog of spadin. Blocks TREK-1 potassium channels, which are involved in serotonin neurotransmission regulation. TREK-1 deletion in mice produces an antidepressant phenotype. PE-22-28 mimics this effect pharmacologically, acting as a rapid-onset antidepressant in rodent models without SSRI lag time.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- cortisol
- pregnancy
- bipolar-disorder
- seizure-disorders
- PMID:23954677PE 22-28, a spadin analog, acts as an antidepressant by blocking TREK-1 channel — Br J Pharmacol, 2013
- PMID:19913560A new antidepressant drug candidate: spadin and TREK-1 — Pharmacol Ther, 2010
PE-22-28 targets a mechanism that SSRIs do not touch. TREK-1 potassium channels modulate serotonin neuron excitability. Blocking them produces antidepressant behavior in mice within 4 days — compared to 3-4 weeks for SSRIs. The speed of onset is the theoretical advantage. The practical limitation is complete. Zero human data. Zero established dosing. Zero safety profile outside of rodent toxicology. The mechanism is novel and the preclinical data is consistent. That is all you can honestly say about it.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See PE-22-28 in a protocol matched to you